Becker's Healthcare January 9, 2026
Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for hospital formularies, prescribing protocols and patient access.
A report published Jan. 8 by GoodRx, “FDA Approval Watch: New Drugs, Vaccines, and Therapies Pending Approval in 2026” outlines several high-impact medications currently under FDA review.
Here are key therapies to watch this year:
1. Anaphylm for anaphylaxis: The sublingual epinephrine film may offer the first needle-free, device-free alternative for treating severe allergic reactions. An FDA decision is expected by Jan. 31.
2. Dupixent for allergic fungal rhinosinusitis: Already approved for multiple inflammatory conditions, the biologic is under review for treating AFRS, a chronic sinus...
Today's Sponsors
Today's Sponsor